The impending arrival of generic versions of Ozempic and Wegovy, two widely used medications, is set to shake up the pharmaceutical landscape in Canada. But here's the catch: while this development is expected to slash insurance costs for employers and workers, it also brings a double-edged sword for the industry. Will the benefits outweigh the potential challenges?
These brand-name semaglutide drugs, prescribed for diabetes and weight loss, are about to lose their market exclusivity in Canada, opening the door for generic pharmaceutical companies to offer more affordable alternatives. This could potentially reduce prices by a staggering 65%, a significant relief for those bearing the financial burden of these medications.
The industry anticipates the launch of at least one generic semaglutide product by summer, with multiple options available by the end of 2026. Insurers are gearing up for this change, informing their clients, known as plan sponsors, about the expected alterations to their group benefit plans.
Pharmacist Frédéric Leblanc, who works on drug management strategies for group insurance clients at iA Financial, believes the introduction of generics will have a substantial impact. He's been in regular discussions with plan sponsors, highlighting the potential cost savings for generic GLP-1 drugs. But he also notes the cyclical nature of the pharmaceutical industry, with new medications constantly emerging and driving up expenses.
The pricing of generic semaglutide is expected to settle at 35% of the Ozempic brand price once multiple generic options are available, offering substantial savings for plan sponsors and members. This is particularly relevant given the recent surge in popularity of weight-loss drugs, with Canadian insurers paying out a whopping $77 million in claims in 2024, up from $38 million the previous year.
The current annual cost of Ozempic, prescribed for diabetes, is approximately $2,899 before additional markups. Wegovy, with a higher semaglutide dose for weight loss, costs around $5,066 annually. But here's where it gets controversial: while the introduction of generics will reduce costs per claim, the overall number of claims is expected to skyrocket.
Colin Ferguson, a senior benefits consultant, emphasizes that this surge in claims is a double-edged sword. Plan sponsors are eager for generics to enter the market, as semaglutide claims have been driving up the cost of employee group benefits. However, this growing demand poses a challenge for private benefit plans funded by employers, directly affecting their financial health.
Currently, only about 30% of plan members insured through iA have coverage for obesity and weight management, which includes Wegovy, compared to the more widely covered Ozempic. But with generic pricing, employers may find it more feasible to include obesity medication in their plans, potentially increasing access to these treatments.
The industry is preparing for this shift, ensuring that everyone can benefit from lower prices for both diabetes and weight management medications. Sunil Hirjee, vice-president of sales at Beneva Inc., raises an intriguing point: should obesity be acknowledged as a chronic condition, similar to Type 2 diabetes, in the context of group benefit plans?
Group benefit plans typically don't cover 100% of a drug's cost, leaving employees to pay a portion out of pocket. With expensive medications, even a 10 or 20% co-pay can be unaffordable. Generics, with their reduced prices, could encourage better medication adherence, but only if effectively communicated to patients.
As the industry awaits the arrival of generics, insurers are preparing for the shift in pricing and reimbursement strategies. Major insurers are closely monitoring the situation, emphasizing the need to balance patient choice and plan sustainability. But will this balance be easily achieved?
The introduction of generics is set to bring about significant changes in the pharmaceutical industry, impacting insurers, employers, and patients alike. Will the benefits of reduced costs outweigh the challenges of increased claims? And how will this shift shape the future of healthcare coverage in Canada? These are questions that will soon be answered as the industry navigates this complex transition.
